Market Herald logo

Subscribe

Be the first with the news that moves the market
  • EMVision Medical Devices (EMV) has made significant progress in commencing clinical trials targeting stroke patients
  • Princess Alexandra’s biomedical engineering department has completed all relevant testing of the EMV brain scanner unit in preparation for trials
  • The company is seeking to commercialise a portable imaging device using electromagnetic microwave imaging
  • The company expects to commence patient scanning shortly
  • EMVision is up 3.45 today with shares trading for 75 cents each

EMVision Medical Devices (EMV) has made significant progress in commencing clinical trials targeting stroke patients.

The medical imaging technology company advised the Princess Alexandra’s biomedical engineering department completed functional and electrical safety testing of the EMV brain scanner unit and key checks needed to progress trials.

EMVision is seeking to commercialise a portable medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications.

“To enter the clinic, on schedule, with a breakthrough technology like ours, is an exciting milestone,” CEO Dr Ron Weinberger said.

“The clinical trial will provide us with valuable learnings and enablement to explore the potential of our technology for diagnosing and monitoring time-sensitive neurological disorders at the point of care in a manner otherwise not possible today,” he added.

Along with clinical work, the company has continued to test the newly fabricated units on several healthy volunteers and showed encouraging progress on the imaging algorithms which will support the trial.

“Our vision is that timely and widespread access to a portable, point-of-care scanning will improve patient survival, reducing personal disability and the community burden of stroke,” Lead Investigator Dr David Cook said.

During the trial, EMVision’s main goal is to collect imaging data from stroke patients that allows refinement and selection of the optimal imaging algorithms as well as early data in correlation with CT and MRI.

The single centre study, up to six months, will enrol 30 diagnosed stroke patients with confirmatory CT and MRI.

It seems EMV’s mission to improve care and monitoring of stroke patients was a standout at the Radiological Society of North America’s 105th Scientific Assembly and Annual Meeting in Chicago.

“This strongly validates our approach of having a small footprint, safe and easy to use device that can be quickly deployed for diagnosis and continuous monitoring,” Ron added.

The company expects to commence patient scanning shortly.

EMVision is up 3.45 today with shares trading for 75 cents each at 11:36 am AEDT.

EMV by the numbers
More From The Market Herald

" Anatara Lifesciences (ASX:ANR) expands eligibility criteria for IBS and psychological functioning trials

Anatara Lifesciences (ASX:ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…

" Apiam Animal Health (ASX:AHX) executes growth strategy with two acquisitions

Apiam Animal Health (ASX:AHX) has announced new acquisitions as part of its growth strategy to double…

" Next Science (ASX:NXS) appoints Oraderm Pharmaceuticals as BlastX distributor

Next Science (ASX:NXS) has signed a multi-year distribution agreement for the sale and distribution of its…